Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of dexmedetomidine versus propofol on hemodynamic and laboratory parameters in uremic secondary hyperparathyroidism
IRCT20190121042444N6Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of dexmedetomidine and propofol in secondary hyperparathyroidism (SHPT) and uremia (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Hemodynamic parameters and Laboratory parameters. Started Aug 2024; status: completed.
02
Drugs
dexmedetomidinepropofol
03
Conditions
secondary hyperparathyroidism (SHPT)uremia
Beyond the preview
Go deeper on IRCT20190121042444N6.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190121042444N6.